Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery
Abstract
1. Introduction
2. Experimental Section
2.1. Subjects of Study
2.2. Clinical and Anthropometric Variables
2.3. Assessment of Weight Change
2.4. Biochemical Variables
2.5. Statistical Analysis
3. Results
3.1. Association Between %EWL and the Variables Studied
3.2. %EWL According to the Type of BS
3.3. %EWL and Comorbidities According the Type of BS
3.4. %EWL According to Sex
3.5. %EWL According to Age
3.6. %EWL and Comorbidities According to Age
3.7. %EWL and Percentage Change (Δ) of Anthropometric and Biochemical Variables
3.8. %EWL and Δ-Anthropometric and Δ-Biochemical Variables According to Type of BS
3.9. %EWL and Δ-Anthropometric and Δ-Biochemical Variables According to Age
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Obesity and Overweight. 2017. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 30 September 2020).
- Sjöström, L.; Narbro, K.; Sjöström, D.; Karason, K.; Larsson, B.; Wedel, H. Effects of bariatric surgery on mortality in swedish obese subjects. N. Engl. J. Med. 2007, 357, 741–752. [Google Scholar] [CrossRef] [PubMed]
- Sjöström, L. Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 2013, 273, 219–234. [Google Scholar] [CrossRef] [PubMed]
- Still, C.D.; Wood, G.C.; Chu, X.; Manney, C.; Strodel, W.; Petrick, A.; Gabrielsen, J.; Mirshahi, T.; Argyropoulos, G.; Seiler, J.; et al. Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery. Obesity 2014, 22, 888–894. [Google Scholar] [CrossRef] [PubMed]
- Camastra, S.; Muscelli, E.; Gastaldelli, A.; Holst, J.J.; Astiarraga, B.D.; Baldi, S.; Nannipieri, M.; Ciociaro, D.; Anselmino, M.; Mari, A.; et al. Long-Term Effects of Bariatric Surgery on Meal Disposal and β-Cell Function in Diabetic and Nondiabetic Patients. Diabetes 2013, 62, 3709–3717. [Google Scholar] [CrossRef] [PubMed][Green Version]
- MacLean, L.D.; Rhode, B.M.; Sampalis, J.; Forse, R.A. Results of the surgical treatment of obesity. Am. J. Surg. 1993, 165, 155–162. [Google Scholar] [CrossRef]
- Maggard, M.A.; Shugarman, L.R.; Suttorp, M.; Maglione, M.; Sugerman, H.J.; Livingston, E.H.; Nguyen, N.T.; Li, Z.; Mojica, W.A.; Hilton, L.; et al. Meta-Analysis: Surgical Treatment of Obesity. Ann. Intern. Med. 2005, 142, 547. [Google Scholar] [CrossRef]
- Sarzynski, M.; Jacobson, P.; Rankinen, T.; Carlsson, B.; Sjöström, L.; Bouchard, C.; Carlsson, L.M.S. Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the SOS bariatric surgery cases. Int. J. Obes. 2010, 35, 676–683. [Google Scholar] [CrossRef]
- Sugerman, H.J.; Londrey, G.L.; Kellum, J.M.; Wolf, L.; Liszka, T.; Engle, K.M.; Birkenhauer, R.; Starkey, J.V. Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment. Am. J. Surg. 1989, 157, 93–102. [Google Scholar] [CrossRef]
- Stefanidis, D.; Kuwada, T.S.; Gersin, K.S. The Importance of the Length of the Limbs for Gastric Bypass Patients—An Evidence-based Review. Obes. Surg. 2010, 21, 119–124. [Google Scholar] [CrossRef]
- Nguyen, N.T.; Rivers, R.; Wolfe, B.M. Factors associated with operative outcomes in laparoscopic gastric bypass. J. Am. Coll. Surg. 2003, 197, 548–555. [Google Scholar] [CrossRef]
- Melton, G.B.; Steele, K.E.; Schweitzer, M.A.; Lidor, A.O.; Magnuson, T.H. Suboptimal Weight Loss after Gastric Bypass Surgery: Correlation of Demographics, Comorbidities, and Insurance Status with Outcomes. J. Gastrointest. Surg. 2007, 12, 250–255. [Google Scholar] [CrossRef]
- Sans, A.; Bailly, L.; Anty, R.; Sielezenef, I.; Gugenheim, J.; Tran, A.; Gual, P.; Iannelli, A. Baseline Anthropometric and Metabolic Parameters Correlate with Weight Loss in Women 1-Year After Laparoscopic Roux-En-Y Gastric Bypass. Obes. Surg. 2017, 27, 2940–2949. [Google Scholar] [CrossRef] [PubMed]
- Campos, G.M. Factors Associated With Weight Loss After Gastric Bypass. Arch. Surg. 2008, 143, 877–884. [Google Scholar] [CrossRef]
- Coupaye, M.; Sabate, J.M.; Castel, B.; Jouët, P.; Clerici, C.; Msika, S.; LeDoux, S. Predictive Factors of Weight Loss 1 Year after Laparoscopic Gastric Bypass in Obese Patients. Obes. Surg. 2010, 20, 1671–1677. [Google Scholar] [CrossRef]
- Barhouch, A.S.; Padoin, A.V.; Casagrande, D.S.; Chatkin, R.; Süssenbach, S.P.; Pufal, M.A.; Rossoni, C.; Mottin, C.C. Predictors of Excess Weight Loss in Obese Patients After Gastric Bypass: A 60-Month Follow-up. Obes. Surg. 2015, 26, 1178–1185. [Google Scholar] [CrossRef]
- Ma, Y.; Pagoto, S.L.; Olendzki, B.C.; Hafner, A.R.; Perugini, R.A.; Mason, R.; Kelly, J.J. Predictors of Weight Status following Laparoscopic Gastric Bypass. Obes. Surg. 2006, 16, 1227–1231. [Google Scholar] [CrossRef]
- Contreras, J.E.; Santander, C.; Court, I.; Bravo, J. Correlation Between Age and Weight Loss after Bariatric Surgery. Obes. Surg. 2013, 23, 1286–1289. [Google Scholar] [CrossRef]
- Garrido-Sanchez, L.; Murri, M.; Rivas-Becerra, J.; Ocaña-Wilhelmi, L.; Cohen, R.; Garcia-Fuentes, E.; Tinahones, F. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. Surg. Obes. Relat. Dis. 2012, 8, 145–150. [Google Scholar] [CrossRef] [PubMed]
- García-Fuentes, E.; Garrido-Sanchez, L.; Garcia-Almeida, J.M.; Garcia-Arnes, J.; Gallego-Perales, J.L.; Rivas-Marin, J.; Morcillo, S.; Cardona, I.; Soriguer, F. Different Effect of Laparoscopic Roux-en-Y Gastric Bypass and Open Biliopancreatic Diversion of Scopinaro on Serum PYY and Ghrelin Levels. Obes. Surg. 2008, 18, 1424–1429. [Google Scholar] [CrossRef] [PubMed]
- De Hollanda, A.; Ruiz, T.; Jiménez, A.; Flores, L.; Lacy, A.; Vidal, J. Patterns of Weight Loss Response Following Gastric Bypass and Sleeve Gastrectomy. Obes. Surg. 2014, 25, 1177–1183. [Google Scholar] [CrossRef]
- Reinhold, R.B. Critical analysis of long term weight loss following gastric bypass. Surg. Gynecol. Obstet. 1982, 155, 385–394. [Google Scholar]
- Christou, N.V.; Look, D.; MacLean, L.D. Weight Gain After Short- and Long-Limb Gastric Bypass in Patients Followed for Longer Than 10 Years. Ann. Surg. 2006, 244, 734–740. [Google Scholar] [CrossRef]
- Shen, S.-W.; Lu, Y.; Li, F.; Yang, C.-J.; Feng, Y.-B.; Li, H.-W.; Yao, W.-F.; Shen, Z.-H. Atherogenic index of plasma is an effective index for estimating abdominal obesity. Lipids Health Dis. 2018, 17, 1–6. [Google Scholar] [CrossRef]
- Lemieux, I.; Lamarche, B.; Couillard, C.; Pascot, A.; Cantin, B.; Bergeron, J.; Dagenais, G.R.; Després, J.-P. Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men. Arch. Intern. Med. 2001, 161, 2685–2692. [Google Scholar] [CrossRef]
- Statements, P. Standards of medical care in diabetes—2012. Diabetes Care 2012, 35 (Suppl. 1), S11–S63. [Google Scholar]
- Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr.; et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003, 289, 2560–2571. [Google Scholar] [CrossRef] [PubMed]
- Brethauer, S.A.; Kim, J.; Chaar, M.E.; Papasavas, P.; Eisenberg, D.; Rogers, A. Standardized outcomes reporting in metabolic and bariatric surgery. Obes. Surg. 2015, 25, 587–606. [Google Scholar] [CrossRef]
- Villarreal-Calderón, J.R.; Cuéllar, R.X.; Ramos-González, M.R.; Rubio-Infante, N.; Castillo, E.C.; Elizondo-Montemayor, L. Interplay between the Adaptive Immune System and Insulin Resistance in Weight Loss Induced by Bariatric Surgery. Oxid. Med. Cell Longev. 2019, 2019, 3940739. [Google Scholar] [CrossRef]
- Cottam, D.R.; Mattar, S.G.; Barinas-Mitchell, E.; Eid, G.; Kuller, L.; Kelley, D.E.; Schauer, P.R. The Chronic Inflammatory Hypothesis for the Morbidity Associated with Morbid Obesity: Implications and Effects of Weight Loss. Obes. Surg. 2004, 14, 589–600. [Google Scholar] [CrossRef]
- Leggio, M.; Lombardi, M.; Caldarone, E.; Severi, P.; D’Emidio, S.; Armeni, M.; Bravi, V.; Bendini, M.G.; Mazza, A. The relationship between obesity and hypertension: An updated comprehensive overview on vicious twins. Hypertens. Res. 2017, 40, 947–963. [Google Scholar] [CrossRef] [PubMed]
- Park, C.H.; Korean Research Group for Endoscopic Management of Metabolic Disorder and Obesity; Nam, S.-J.; Choi, H.S.; Kim, K.O.; Kim, D.H.; Kim, J.-W.; Sohn, W.; Yoon, J.H.; Jung, S.H.; et al. Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Obes. Surg. 2019, 29, 2180–2190. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; He, J.; Wang, H.; Zhu, D.; Bi, Y. Adipose Morphology: A Critical Factor in Regulation of Human Metabolic Diseases and Adipose Tissue Dysfunction. Obes. Surg. 2020, 1–15. [Google Scholar] [CrossRef] [PubMed]
- Garrido-Sánchez, L.; Tomé, M.; Santiago-Fernández, C.; García-Serrano, S.; García-Fuentes, E.; Tinahones, F.J. Adipose tissue biomarkers involved in early resolution of type 2 diabetes after bariatric surgery. Surg. Obes. Relat. Dis. 2017, 13, 70–77. [Google Scholar] [CrossRef] [PubMed]
- Diamantis, T.; Apostolou, K.G.; Alexandrou, A.; Griniatsos, J.; Felekouras, E.; Tsigris, C. Review of long-term weight loss results after laparoscopic sleeve gastrectomy. Surg. Obes. Relat. Dis. 2014, 10, 177–183. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Zhou, X.; Li, L.; Li, S.; Tan, J.; Li, Y.; Sun, X. The Long-Term Effects of Bariatric Surgery for Type 2 Diabetes: Systematic Review and Meta-analysis of Randomized and Non-randomized Evidence. Obes. Surg. 2014, 25, 143–158. [Google Scholar] [CrossRef]
- Printen, K.J.; Mason, E.E. Gastric bypass for morbid obesity in patients more than fifty years of age. Surg. Gynecol. Obstet. 1977, 144, 192–194. [Google Scholar]
- Livingston, E.H.; Huerta, S.; Arthur, D.; Lee, S.; De Shields, S.; Heber, D. Male Gender is a Predictor of Morbidity and Age a Predictor of Mortality for Patients Undergoing Gastric Bypass Surgery. Ann. Surg. 2002, 236, 576–582. [Google Scholar] [CrossRef]
- Dobiášová, M. Atherogenic Index of Plasma [Log(Triglycerides/HDL-Cholesterol)]: Theoretical and Practical Implications. Clin. Chem. 2004, 50, 1113–1115. [Google Scholar] [CrossRef]
- Murri, M.; García-Fuentes, E.; García-Almeida, J.M.; Garrido-Sanchez, L.; Mayas, M.D.; Bernal, R.; Tinahones, F.J. Changes in Oxidative Stress and Insulin Resistance in Morbidly Obese Patients After Bariatric Surgery. Obes. Surg. 2009, 20, 363–368. [Google Scholar] [CrossRef]
- Piché, M.-È.; Martin, J.; Cianflone, K.; Bastien, M.; Marceau, S.; Biron, S.; Hould, F.-S.; Poirier, P. Changes in predicted cardiovascular disease risk after biliopancreatic diversion surgery in severely obese patients. Metabolism 2014, 63, 79–86. [Google Scholar] [CrossRef]
- Perathoner, A.; Weißenbacher, A.; Sucher, R.; Laimer, E.; Pratschke, J.; Mittermair, R. Significant Weight Loss and Rapid Resolution of Diabetes and Dyslipidemia During Short-Term Follow-Up After Laparoscopic Sleeve Gastrectomy. Obes. Surg. 2013, 23, 1966–1972. [Google Scholar] [CrossRef] [PubMed]
- Khaitan, L.; Shea, B.J. Laparoscopic vertical sleeve gastrectomy, long and short-term impact on weight loss and associated co-morbidities. Ann. Transl. Med. 2020, 8, S5. [Google Scholar] [CrossRef]
- Bhandari, M.; Reddy, M.; Kosta, S.; Mathur, W.; Fobi, M.; Mohit, B.; Manoj, R.; Susmit, K.; Winni, M.; Mathias, F. Laparoscopic sleeve gastrectomy versus laparoscopic gastric bypass: A retrospective cohort study. Int. J. Surg. 2019, 67, 47–53. [Google Scholar] [CrossRef] [PubMed]
- Osland, E.; Yunus, R.M.; Khan, S.; Memon, B.; Memon, M.A. Weight Loss Outcomes in Laparoscopic Vertical Sleeve Gastrectomy (LVSG) Versus Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) Procedures. Surg. Laparosc. Endosc. Percutaneous Tech. 2017, 27, 8–18. [Google Scholar] [CrossRef]
Pre-Surgery | |||
---|---|---|---|
BPD | RYGB | SG | |
N (%) | 66 | 83 | 180 |
Sex (men/women) | 24/42 | 20/63 | 59/121 |
Age (years) | 42.9 ± 9.6 | 43.9 ± 9.4 | 44.1 ± 10.1 |
Weight (Kg) | 147.4 ± 22.8 a | 135.3 ± 23.7 b | 135.1 ± 23.7 b |
BMI (kg/m2) | 53.8 ± 6.5 a | 49.7 ± 8.0 b | 50.2 ± 7.7 b |
Waist (cm) | 141.4 ± 16.7 a | 135.8 ± 15.4 b | 134.4 ± 13.4 b |
Hip (cm) | 152.6 ± 13.3 a | 147.6 ± 17.2 b | 146.1 ± 14.9 b |
SBP (mmHg) | 138.5 ± 20.9 | 137.9 ± 18.3 | 137.5 ± 19.1 |
DBP (mmHg) | 84.9 ± 14.5 | 81.7 ± 12.5 | 83.0 ± 10.4 |
Glucose (mg/dL) | 117.1 ± 40.6 a | 119.8 ± 51.9 a | 104.8 ± 49.9 b |
Total cholesterol (mg/dL) | 193.3 ± 44.9 | 197.8 ± 37.0 | 187.5 ± 33.7 |
Triglycerides (mg/dL) * | 151.3 (101.2–208.0) | 127.0 (99.0–184.0) | 122.0 (77.1–145.5) |
HDL (mg/dL) | 44.6 ± 10.4 | 47.1 ± 11.5 | 44.4 ± 11.3 |
LDL (mg/dL) | 119.9 ± 36.3 | 121.6 ± 31.6 | 109.8 ± 31.7 |
Insulin (μIU/mL) * | 19.2 (16.2–24.3) | 15.3 (13.2–21.9) | 13.1 (11.1–20.4) |
HOMA-IR * | 5.03 (4.2–7.7) | 4.01 (3.3–6.2) | 3.6 (2.6–4.9) |
Leptin (ng/mL) * | 58.8 (52.3–84.6) | 62.3 (49.0–81.5) | 41.9 (33.4–57.4) |
Adiponectin (µg/mL) | 8.8 ± 4.5 | 7.9 ± 3.8 | 8.2 ± 3.5 |
CRP (mg/L) * | 5.3 (3.9–9.3) | 9.7 (7.8–16.4) | 3.3 (1.5–8.1) |
TG/HDL * | 3.7 (1.9–5.6) | 2.7 (2.1–3.5) | 2.1 (1.7–3.2) |
TC/HDL | 4.3 ± 1.2 | 4.3 ± 1.1 | 4.3 ± 1.2 |
AIP | 0.46 ± 0.26 | 0.45 ± 0.27 | 0.47 ± 0.27 |
Comorbilities | |||
%Patients with T2DM (n) | 39.4 (26) | 44.6 (37) | 32.7 (59) |
%Patients with hypertension (n) | 74.3 (49) | 82.0 (68) | 72.7 (131) |
%Patients with hypercholesterolemia (n) | 47.0 (31) | 67.5 (56) | 41.7 (75) |
Pre-Surgery | Post-Surgery | |||
---|---|---|---|---|
%EWL <50% | %EWL ≥50% | %EWL <50% | %EWL ≥50% | |
N (%) | 64 (19.4%) | 265 (80.6%) | 64 (19.4%) | 265 (80.6%) |
Sex (men/women) | 18/46 | 85/180 | ||
Age (years) | 46.6 ± 10.2 | 43.9 ±9.7 1 | ||
Weight (Kg) | 142.2 ± 24.9 | 137.1 ± 23.7 | 111.9 ± 17.6 ‡ | 87.9 ± 14.1 2,‡ |
BMI (kg/m2) | 53.4 ± 8.6 | 50.1 ± 7.4 1 | 42.0 ± 5.8 ‡ | 32.1 ± 4.5 2,‡ |
Waist (cm) | 140.9 ± 14.3 | 136.6 ± 15.8 | 120.0 ± 12.5 ‡ | 102.4 ± 12.2 2,‡ |
Hip (cm) | 152.5 ± 14.5 | 147.1 ± 15.4 1 | 132.1 ± 12.1 ‡ | 113.5 ± 12.8 2,‡ |
SBP (mmHg) | 142.8 ± 19.9 | 137.8 ± 18.6 | 131.6 ± 19.6 ‡ | 127.9 ± 20.4 ‡ |
DBP (mmHg) | 84.5 ± 10.7 | 82.7 ± 11.9 | 81.4 ± 13.0 ‡ | 76.7 ± 12.3 1,‡ |
Glucose (mg/dL) | 115.3 ± 34.1 | 110.7 ± 41.9 | 91.6 ± 12.2 ‡ | 83.9 ± 15.5 2,‡ |
Total cholesterol (mg/dL) | 196.7 ± 39.1 | 188.1 ± 36.7 | 182.3 ± 50.6 | 173.7 ± 38.2 ‡ |
Triglycerides (mg/dL) * | 183.0 (123.2–234.5) | 122.1 (92.9–168.0) | 147.0 (106.5–168.0) † | 82.0 (60.5–114.0) 2,‡ |
HDL (mg/dL) | 44.9 ± 10.9 | 45.5 ± 11.3 | 50.7 ± 15.5 † | 53.7 ± 13.3 ‡ |
LDL (mg/dL) | 120.8 ± 34.0 | 113.9 ± 32.2 | 108.8 ± 40.0 | 103.5 ± 32.8 ‡ |
Insulin (μIU/mL) * | 15.3 (13.4–20.6) | 17.1 (12.9–23.6) | 9.1 (7.4–11.4) ‡ | 7.5 (5.2–9.1) 2,‡ |
HOMA-IR * | 4.3 (3.5–5.5) | 4.4 (3.3–6.7) | 2.1 (1.5–2.4) ‡ | 1.5 (1.1–1.9) 2,‡ |
Leptin (ng/mL) * | 78.4 (45.8–88.1) | 58.2 (43.7–75.0) | 25.4 (15.1–39.2) ‡ | 12.0 (8.8–16.0) 2,‡ |
Adiponectin (µg/mL) | 9.1 ± 4.0 | 7.9 ± 4.1 | 11.1 ± 5.3 | 13.8 ± 6.7 ‡ |
CRP (mg/L) * | 7.5 (5.7–11.7) | 8.1 (3.9–11.4) | 0.3 (0.2–1.7) † | 0.7 (0.3–2.3) ‡ |
TG/HDL * | 4.0 (2.7–5.9) | 2.6 (1.9–3.6) | 3.1 (2.9–4.0) ‡ | 1.6 (1.0–2.4) 2,‡ |
TC/HDL | 4.6 ± 1.2 | 4.3 ± 1.1 | 3.7 ± 1.1 ‡ | 3.3 ± 0.9 1,‡ |
AIP | 0.50 ± 0.26 | 0.45 ± 0.27 | 0.36 ± 0.25 ‡ | 0.19 ± 0.21 2,‡ |
Comorbilities | ||||
%Patients with T2DM (n) | 45.3 (29) | 35.4 (94) | 3.2 (2) † | 0.8 (2) ‡ |
%Patients with hypertension (n) | 82.8 (53) | 73.5 (195) | 60.9 (39) † | 49.1 (130) ‡ |
%Patients with hypercholesterolemia (n) | 56.2 (36) | 48.3 (128) | 39.0 (25) † | 28.3 (75) ‡ |
B Coefficient | p | OR | (95% Confidence Interval) | |
---|---|---|---|---|
Sex (women = 0/men = 1) | −0.462 | 0.449 | 0.630 | 0.191–2.081 |
Age | −0.066 | 0.050 | 0.936 | 0.876–0.999 |
BMI | −0.001 | 0.977 | 0.999 | 0.913–1.092 |
Hypertension (yes = 0/no = 1) | −0.673 | 0.416 | 0.510 | 0.101–2.579 |
AIP | −3.188 | 0.019 | 0.041 | 0.003–0.591 |
Type of surgery | 0.045 | |||
Type of surgery (SG) | 0.958 | 0.196 | 2.607 | 0.610–11.147 |
Type of surgery (RYGB) | 1.850 | 0.014 | 6.360 | 1.465–27.606 |
HOMA-IR | 0.106 | 0.227 | 1.112 | 0.936–1.320 |
CRP | −0.015 | 0.692 | 0.985 | 0.914–1.062 |
%EWL <50% | %EWL ≥50% | |||||
---|---|---|---|---|---|---|
BPD | RYGB | SG | BPD | RYGB | SG | |
N (% within each type of BS) | 21 (31.8%) | 11 (13.3%) | 32 (17.8%) | 45 (68.2%) | 72 (86.7%) | 148 (82.2%) |
Sex (men/women) | 8/13 | 2/9 | 8/24 | 16/29 | 18/54 | 51/97 |
Age (years) | 42.0 ± 8.9 | 46.6 ± 11.8 | 48.1 ± 9.9 | 41.6 ± 10.1 | 43.5 ± 9.1 | 44.4 ± 9.9 |
Weight (Kg) | 148.9 ± 24.6 | 137.8 ± 23.5 | 137.5 ± 26.6 | 146.6 ± 21.6 a | 134.8 ± 23.1 b | 134.7 ± 23.8 b |
BMI (kg/m2) | 54.4 ± 7.8 | 52.4 ± 8.2 | 52.3 ± 9.8 | 53.5 ± 5.9 a | 49.9 ± 7.6 b | 49.2 ± 7.4 b |
Waist (cm) | 143.8 ± 14.7 | 135.0 ± 13.2 | 139.5 ± 13.8 | 140.3 ± 15.8 | 137.1 ± 16.2 | 135.1 ± 15.6 |
Hip (cm) | 153.6 ± 10.4 | 147.5 ± 20.3 | 150.6 ± 14.7 | 152.2 ± 13.3 a | 147.6 ± 16.9 a,b | 145.2 ± 14.8 b |
SBP (mmHg) | 138.0 ± 23.5 | 134.6 ± 5.5 | 145.1 ± 17.4 | 138.7 ± 20.2 | 137.6 ± 18.2 | 136.7 ± 18.2 1 |
DBP (mmHg) | 84.4 ± 15.1 | 77.0 ± 3.4 | 85.7 ± 8.8 | 85.1 ± 14.9 | 82.1 ± 12.8 | 82.5 ± 10.8 |
Glucose (mg/dL) | 120.2 ± 31.6 | 116.2 ± 52.9 | 105.7 ± 20.1 | 115.4 ± 44.9 a,b | 120.2 ± 52.2 a | 103.4 ± 32.9 b,1 |
Total cholesterol (mg/dL) | 200.0 ± 42.9 | 207.6 ± 45.8 | 183.4 ± 31.6 | 189.6 ± 46.1 a,b | 196.5 ± 35.9 a | 182.3 ± 34.2 b |
Triglycerides (mg/dL) * | 165.5 (130.0–210.0) | 175.0 (96.0–183.0) | 179.0 (143.0–222.0) | 105.0 (87.0–169.0) b,1 | 138.5 (100.0–202.0) a | 110.0 (75.5–128.4) a,b |
HDL (mg/dL) | 40.6 ± 10.4 b | 50.0 ± 9.3 a | 45.4 ± 11.7 a,b | 46.7 ± 9.8 1 | 46.7 ± 11.8 | 44.2 ± 11.2 |
LDL (mg/dL) | 125.7 ± 39.6 | 129.0 ± 40.7 | 109.3 ± 25.3 | 117.2 ± 34.5 | 118.3 ± 32.7 | 109.9 ± 33.0 |
Insulin (μIU/mL) * | 17.9 (13.3–22.2) | 17.0 (13.7–25.8) | 12.5 (11.9–15.4) | 22.2 (16.7–28.6) | 16.9 (13.5–24.1) | 17.3 (11.0–22.5) |
HOMA-IR * | 5.4 (4.2–6.4) | 4.1 (3.4–9.9) | 3.5 (2.9–4.3) | 6.9 (4.2–9.2) | 4.3 (3.3–6.8) | 3.8 (2.7–5.5) |
Leptin (ng/mL) * | 88.1 (57.7–91.2) | 78.7 (42.0–122.3) | 39.8 (39.5–106.0) | 56.8 (51.0–67.0) 1 | 63.2 (46.0–94.0) | 43.8 (35.5–68.8) |
Adiponectin (µg/mL) | 8.6 ± 4.2 | 9.1 ± 4.4 | 9.8 ± 2.3 | 8.8 ± 4.7 | 7.1 ± 3.7 | 7.9 ± 3.6 |
CRP (mg/L) * | 5.9 (3.4–9.4) | 7.9 (2.4–15.6) | 9.4 (4.8–10.8) | 4.3 (3.0–9.8) a,b | 8.5 (3.8–12.7) a | 3.3 (1.4–9.2) b |
TG/HDL * | 3.7 (2.9–5.8) | 3.1 (2.5–3.5) | 2.8 (2.5–5.0) | 2.5 (1.7–3.9) 2 | 3.0 (2.0–4.0) | 2.2 (1.5–3.1) |
TC/HDL | 5.2 ± 1.2 a | 4.2 ± 0.8 b | 4.2 ± 1.2 b | 4.1 ± 1.1 2 | 4.4 ± 1.2 | 4.3 ± 1.2 |
AIP | 0.60 ± 0.27 | 0.43 ± 0.19 | 0.47 ± 0.27 | 0.38 ± 0.23 2 | 0.47 ± 0.28 | 0.47 ± 0.27 |
Comorbilities | ||||||
%Patients with T2DM (n) | 42.9 (9) | 36.7 (4) | 46.8 (15) | 37.8 (17) | 45.8 (33) | 29.1 (43) 1 |
%Patients with hypertension (n) | 66.7 (14) | 100.0 (11) | 87.5 (28) | 80.0 (36) | 80.5 (58) | 69.6 (103) 1 |
%Patients with hypercholesterolemia (n) | 57.1 (12) | 81.8 (9) | 40.6 (13) | 42.2 (19) | 65.3 (47) | 41.9 (62) |
%EWL <50% | %EWL ≥50% | |||||||
---|---|---|---|---|---|---|---|---|
≤37 Years | 37–44 Years | 45–52 Years | >52 Years | ≤37 Years | 37–44 Years | 45–52 Years | >52 Years | |
N (% within each group of age) | 12 (14.5%) | 14 (17.3%) | 17 (21.3%) | 21 (24.7%) | 71 (85.5%) | 67 (82.7%) | 63 (78.7%) | 64 (75.3%) |
Sex (men/women) | 4/8 | 5/9 | 5/12 | 4/17 | 23/48 | 16/51 | 23/40 | 23/41 |
Age (years) | 31.2 ± 4.6 d | 40.6 ± 1.9 c | 48.7 ± 2.1 b | 57.9 ± 2.4 a | 31.4 ± 4.7 d | 41.4 ± 1.8 c | 47.8 ± 2.1 b | 56.4 ± 3.4 a,1 |
Weight (Kg) | 146.2 ± 28.1 a,b | 159.9 ± 24.5 a | 137.7 ± 20.9 b,c | 128.2 ± 21.4 c | 144.9 ± 24.9 a | 133.3 ± 21.0 b,2 | 137.0 ± 22.8 b | 131.8 ± 23.2 b |
BMI (kg/m2) | 52.6 ± 10.5 a,b | 58.6 ± 7.8 a | 51.2 ± 8.9 b | 51.3 ± 7.0 b | 51.8 ± 8.1 a | 49.7 ± 7.6 a,b,2 | 49.4 ± 6.4 a,b | 49.1 ± 7.0 b |
Waist (cm) | 148.6 ± 16.6 a | 146.4 ± 16.7 a,b | 134.7 ± 11.2 c | 136.9 ± 13.3 b,c | 137.3 ± 16.9 a,b | 132.6 ± 15.4 b,2 | 136.9 ± 14.2 a,b | 139.1 ± 15.6 a |
Hip (cm) | 152.9 ± 18.8 | 156.8 ± 15.4 | 149.3 ± 13.1 | 149.8 ± 14.9 | 151.0 ± 16.4 a | 146.2 ± 14.2 a,b,2 | 144.7 ± 16.3 b | 145.7 ± 13.6 ab |
SBP (mmHg) | 127.8 ± 9.8 b | 135.2 ± 12.4 b | 138.7 ± 22.2 b | 156.7 ± 15.8 a | 135.6 ± 15.5 b | 135.3 ± 18.2 b | 136.1 ± 20.6 b | 143.2 ± 20.1 a,1 |
DBP (mmHg) | 83.8 ± 8.9 | 83.5 ± 9.3 | 83.6 ± 13.8 | 86.6 ± 9.3 | 82.0 ± 11.2 | 83.8 ± 12.1 | 81.3 ± 12.0 | 83.8 ± 12.2 |
Glucose (mg/dL) | 111.7 ± 40.6 | 127.0 ± 38.3 | 107.1 ± 25.6 | 114.3 ± 33.6 | 97.0 ± 31.0 c | 107.1 ± 31.3 b,c,2 | 111.6 ± 46.6 b | 126.2 ± 50.2 a |
Total cholesterol (mg/dL) | 189.7 ± 35.2 | 198.2 ± 45.3 | 185.1 ± 39.9 | 206.4 ± 36.5 | 184.7 ± 36.6 | 185.4 ± 37.2 | 190.2 ± 37.3 | 190.7 ± 36.5 |
Triglycerides (mg/dL) * | 194.5 (127.5–351.4) | 1710 (150.5–216.0) | 149.9 (112.7–185.4) | 179.0 (122.5–193.0) | 117.5 (71.0–147.0) b | 120.0 (89.5–187.5) ab,1 | 105.0 (88.0–157.0) b | 138.8 (121.0–209.0) a |
HDL (mg/dL) | 40.1 ± 8.1 b | 43.0 ± 11.2 b | 40.9 ± 9.4 b | 52.8 ± 10.8 a | 43.6 ± 11.7 | 45.4 ± 12.1 | 45.9 ± 9.4 1 | 46.7 ± 11.9 1 |
LDL (mg/dL) | 114.5 ± 23.9 | 119.1 ± 39.1 | 118.0 ± 37.1 | 125.0 ± 33.4 | 114.2 ± 28.0 | 114.3 ± 34.1 | 114.3 ± 35.0 | 112.2 ± 33.0 |
Insulin (μIU/mL) * | 15.2 (12.1–23.4) | 25.8 (20.3–33.6) | 13.1 (11.9–16.3) | 15.4 (13.1–18.8) | 18.4 (12.8–29.4) | 18.1 (12.8–24.5) | 20.1 (15.1–24.0) | 16.8 (13.1–23.5) |
HOMA-IR * | 5.6 (4.1–6.1) | 9.4 (5.9–14.2) | 4.0 (3.0–4.3) | 3.9 (3.3–4.7) | 4.1 (2.7–7.5) | 4.7 (3.5–6.9) 1 | 5.1 (3.8–7.5) | 4.3 (3.3–7.1) |
Leptin (ng/mL) * | 67.0 (37.1–98.7) | 90.7 (83.6–93.5) | 60.8 (34.0–91.2) | 68.3 (39.6–109.0) | 59.1 (49.0–83.3) | 53.4 (41.0–85.4) | 62.3 (35.9–82.9) | 53.0 (38.0–64.2) |
Adiponectin (µg/mL) | 5.4 ± 2.6 b | 7.9 ± 5.8 a,b | 9.8 ± 2.4 a | 10.8 ± 3.2 a | 7.5 ± 3.7 | 8.5 ± 4.7 | 8.6 ± 3.8 | 8.9 ± 3.9 |
CRP (mg/L) * | 7.8 (4.3–28.9) | 8.3 (4.1–17.7) | 4.9 (3.4–5.7) | 8.5 (5.5–13.2) | 8.3 (3.4–11.3) | 4.2 (1.8–8.9) | 7.3 (1.7–11.8) | 7.3 (3.8–9.8) |
TG/HDL * | 4.6 (3.3–11.5) | 4.2 (2.8–5.8) | 3.0 (2.9–4.0) | 2.8 (2.5–4.2) | 2.6 (1.5–3.1) | 2.6 (1.7–3.9) 1 | 2.2 (2.0–3.5) | 3.1 (2.1–5.6) |
TC/HDL | 4.8 ± 1.3 | 4.8 ± 1.4 | 4.6 ± 1.1 | 4.1 ± 0.9 | 4.4 ± 1.3 | 4.4 ± 1.2 | 4.2 ± 1.0 | 4.2 ± 1.2 |
AIP | 0.55 ± 0.29 | 0.59 ± 0.27 | 0.51 ± 0.24 | 0.41 ± 0.26 | 0.43 ± 0.26 | 0.41 ± 0.27 1 | 0.45 ± 0.25 | 0.51 ± 0.29 |
Comorbidities | ||||||||
%Patients with T2DM (n) | 25.0 (3) | 57.1 (8) | 47.0 (8) | 47.6 (10) | 18.3 (13) | 26.8 (18) 1 | 34.9 (22) | 62.5 (40) |
%Patients with hypertension (n) | 58.3 (7) | 64.2 (9) | 82.4 (14) | 100.0 (21) | 59.1 (42) | 74.6 (50) | 77.8 (49) | 84.3 (54) 1 |
%Patients with hypercholesterolemia (n) | 41.7 (5) | 71.4 (10) | 35.3 (6) | 71.4 (15) | 35.2 (25) | 43.2 (29) 1 | 50.8 (32) | 68.8 (44) |
%EWL <50% | %EWL ≥50% | |||||
---|---|---|---|---|---|---|
BPD | RYGB | SG | BPD | RYGB | SG | |
Δ-Weight | 20.9 ± 7.5 | 22.1 ± 7.3 | 20.0 ± 5.2 | 34.3 ± 5.8 b,3 | 36.0 ± 6.6 a,3 | 35.2 ± 7.6 a,b,3 |
Δ-BMI | 20.9 ± 7.5 | 22.1 ± 7.3 | 20.0 ± 5.2 | 34.3 ± 5.8 b,3 | 36.0 ± 6.6 a,3 | 35.2 ± 7.6 a,b,3 |
Δ-Waist | 17.7 ± 5.5 a | 12.6 ± 7.1 b | 14.2 ± 5.5 a,b | 22.4 ± 6.1 b,1 | 25.4 ± 8.1 a,3 | 24.9 ± 7.7 a,b,3 |
Δ-Hip | 14.2 ± 3.7 | 11.0 ± 9.2 | 12.6 ± 3.9 | 21.2 ± 5.6 3 | 23.2 ± 14.1 3 | 22.3 ± 6.6 3 |
Δ-SBP | 9.9 ± 10.5 | 7.1 ± 20.1 | 6.6 ± 12.0 | 9.7 ± 13.6 | 8.1 ± 13.8 | 6.2 ± 15.2 |
Δ-DBP | 11.3 ± 12.9 | 2.6 ± 16.9 | 0.7 ± 16.0 | 8.4 ± 16.7 | 4.7 ± 22.5 | 5.1 ± 17.3 |
Δ-Glucose | 20.5 ± 16.4 a | 22.4 ± 19.8 a | 9.0 ± 14.3 b | 20.7 ± 17.8 a,b | 24.6 ± 21.9 a | 14.6 ± 16.4 b |
Δ-Cholesterol | 31.6 ± 14.8 a | −0.5 ± 15.6 b | −10.7 ± 24.2 b | 24.9 ± 18.0 a | 11.2 ± 22.6 b,1 | −6.0 ± 21.9 c |
Δ-Triglycerides * | 24.9 (2.9–58.9) | 18.9 (8.6–41.2) | 5.46 (−10.9–26.2) | 12.8 (−12.9–30.3) b | 34.6 (13.1–51.1) a | 41.0 (4.3–50.3) a,2 |
Δ-HDL | 0.8 ± 29.0 a | −8.8 ± 25.1 a,b | −30.5 ± 44.2 b | −3.7 ± 26.5 a | −20.2 ± 27.8 b | −30.2 ± 31.1 b |
Δ-LDL | 38.4 ± 14.0 a | −5.5 ± 30.9 b | −11.3 ± 36.2 b | 35.2 ± 21.2 a | 11.2 ± 34.2 a,b | −2.3 ± 103.0 c |
Δ-Insulin * | 47.4 (40.9–60.7) | 20.1 (13.2–35.1) | 16.3 (13.2–29.3) | 62.9 (55.3–70.9) 2 | 54.6 (37.9–67.2) | 58.4 (44.1–70.6) 3 |
Δ-HOMA-IR * | 55.5 (46.2–77.6) | 26.8 (21.6–39.8) | 32.3 (29.1–42.4) | 73.5 (64.1–76.8) 1 | 67.4 (52.3–77.7) | 60.6 (51.7–77.2) 3 |
Δ-Leptin * | 53.2 (47.8–69.6) | 52.3 (48.5–61.2) | 51.9 (50.8–56.5) | 85.4 (77.9–88.3) 2 | 76.9 (70.7–85.1) 2 | 76.6 (64.0–79.9) 1 |
Δ-Adiponectin | −12.0 ± 37.0 | −82.7 ± 59.5 | −55.9 ± 60.1 | −33.5 ± 56.0 a | −119.1 ± 150.4 b | −156.0 ± 124.3 b |
Δ-CRP * | 95.8 (87.7–97.2) a | 71.7 (65.4–82.2) a,b | 65.2 (54.9–71.8) b | 84.8 (72.1–93.2) | 83.8 (66.6–94.2) | 89.2 (60.2–91.9) 3 |
Δ-TG/HDL * | 31.4 (11.0–45.5) | 35.7 (15.6–49.7) | 8.8 (−17.4–34.6) | 0.23 (−12.9–24.7) b | 47.5 (26.1–61.1) a | 52.6 (7.7–62.7) a,1 |
Δ-TC/HDL | 28.1 ± 17.9 a | 2.6 ± 29.7 b | 9.2 ± 25.6 b | 25.0 ± 16.4 a | 23.4 ± 19.8 a,1 | 15.2 ± 22.0 b |
Δ-AIP | 53.1 ± 154.0 | 19.9 ± 98.1 | 53.1 ± 77.6 | 21.2 ± 213.1 b | 49.6 ± 72.2 a,b | 70.0 ± 87.9 a,1 |
%EWL <50% | %EWL ≥50% | |||||||
---|---|---|---|---|---|---|---|---|
≤37 Years | 37–44 Years | 45–52 Years | >52 Years | ≤37 Years | 37–44 Years | 45–52 Years | >52 Years | |
Δ-Weight | 20.4 ± 6.3 | 23.5 ± 5.9 | 19.3 ± 7.1 | 19.5 ± 5.5 | 39.6 ± 7.3 a,3 | 34.8 ± 6.6 b,3 | 33.8 ± 6.0 b,3 | 32.9 ± 5.8 b,3 |
Δ-BMI | 20.4 ± 6.3 | 23.5 ± 5.9 | 19.3 ± 7.1 | 19.5 ± 5.5 | 39.6 ± 7.3 a,3 | 34.8 ± 6.6 b,3 | 33.8 ± 6.0 b,3 | 32.9 ± 5.8 b,3 |
Δ-Waist | 15.1 ± 5.2 | 15.8 ± 6.3 | 14.5 ± 5.1 | 14.8 ± 6.9 | 27.8 ± 6.8 a,3 | 23.7 ± 9.1 b,2 | 23.1 ± 5.2 b,3 | 23.1 ± 7.5 b,3 |
Δ-Hip | 12.9 ± 4.7 | 13.7 ± 6.4 | 13.4 ± 4.0 | 11.8 ± 4.9 | 25.2 ± 6.7 a,3 | 23.2 ± 10.3 a,b,3 | 19.8 ± 10.8 c,3 | 20.6 ± 5.6 b,c,3 |
Δ-SBP | 3.6 ± 9.8 | 4.9 ± 9.8 | 5.7 ± 16.2 | 13.1 ± 8.3 | 12.0 ± 12.2 a,1 | 6.3 ± 14.4 b | 4.3 ± 15.1 b | 5.4 ± 15.9 b |
Δ-DBP | 7.1 ± 14.4 | 0.5 ± 11.6 | 0.4 ± 21.0 | 6.4 ± 14.8 | 11.4 ± 15.6 a | 6.3 ± 17.8 a,b | −0.6 ± 17.5 b | 3.8 ± 19.9 b |
Δ-Glucose | 14.7 ± 19.1 a,b | 25.1 ± 16.5 a | 9.7 ± 17.5 b | 12.9 ± 12.2 ª,b | 12.8 ± 19.1 c | 16.1 ± 15.4 b,c | 19.5 ± 17.5 a,b | 24.5 ± 18.7 a,1 |
Δ-Cholesterol | 18.2 ± 20.2 a | 11.3 ± 27.4 a,b | −1.6 ± 32.7 a,b | −3.1 ± 24.0 b | 9.4 ± 21.6 | 3.4 ± 25.7 | 4.6 ± 23.8 | −1.2 ± 26.8 |
Δ-Triglycerides * | 66.7 (58.3−75.2) | 22.4 (−2.5–40.9) | −15.6 (−23.5–2.9) | 27.5 (16.5–37.2) | 25.0 (10.5–50.1) | 23.9 (−3.4–55.5) | 32.8 (15.8–45.2) 1 | 35.5 (−1.1–53.8) 1 |
Δ-HDL | −1.2 ± 15.4 a | −0.6 ± 23.8 a | −45.5 ± 55.8 b | −12.0 ± 29.1 a | −22.3 ± 30.7 1 | −24.7 ± 34.8 1 | −24.5 ± 28.0 | −22.5 ± 31.9 |
Δ-LDL | 14.7 ± 21.1 | 6.8 ± 38.0 | 4.5 ± 42.7 | −10.6 ± 36.8 | 9.7 ± 30.2 | 0.9 ± 40.0 | 24.7 ± 145.6 | −7.0 ± 45.7 |
Δ-Insulin * | 46.8 (43.2–50.5) | 70.8 (40.5–78.7) | 44.3 (41.4–47.5) | 32.6 (24.5–37.4) | 58.3 (50.1–63.3) 2 | 58.8 (38.6–68.3) | 53.4 (40.7–68.7) 3 | 58.8 (24.7–72.9) 2 |
Δ-HOMA-IR * | 62.5 (47.5–77.6) | 77.7 (54.9–84.9) | 53.2 (49.0–55.4) | 43.0 (34.5–47.8) | 66.6 (56.3–73.1) a,1 | 71.0 (50.1–77.1) b | 67.7 (52.6–79.1) a,b,3 | 72.0 (51.7–78.5) a,b,2 |
Δ-Leptin * | 53.2 (50.8–55.6) | 49.7 (49.2–70.8) | 47.0 (40.3–59.6) | 61.1 (56.5–64.1) | 82.1 (73.3–88.2) 1 | 75.7 (65.9–81.5) | 77.6 (71.0–85.0) 2 | 79.9 (62.3–83.8) 1 |
Δ-Adiponectin | −54.1 ± 25.6 | −10.8 ± 43.9 | −1.7 ± 39.4 | −50.1 ± 58.6 | −91.6 ± 92.2 a | −81.2 ± 101.0 a | −213.7 ± 193.9 b,1 | −105.1 ± 82.3 a |
Δ-CRP * | 96.8 (95.9–97.8) | 93.3 (85.9–96.2) | 82.1 (78.7–88.9) | 65.2 (54.9–80.9) | 91.7 (80.7–96.1) | 79.1 (50.4–87.8) | 81.1 (69.4–91.3) | 85.5 (54.4–95.4) |
Δ-TG/HDL * | 62.2 (50.1–74.2) | 20.1 (−11.7–30.5) | 1.9 (−27.5–15.0) | 34.6 (21.7–47.5) | 29.4 (7.7–58.3) | 50.3 (−5.5–53.4) | 48.3 (19.3–60.8) | 46.2 (−9.6–58.1) 1 |
Δ-TC/HDL | 17.5 ± 24.9 a,b | 9.9 ± 27.2 a,b | 24.8 ± 24.6 a | 3.1 ± 24.1 b | 22.8 ± 20.1 | 18.8 ± 20.1 | 21.5 ± 22.6 | 14.8 ± 20.8 1 |
Δ-AIP | 18.7 ± 39.0 a,b | 9.4 ± 73.4 b | 95.4 ± 175.0 a | 46.9 ± 58.7 a,b | 43.2 ± 77.0 1 | 37.4 ± 150.0 1 | 79.2 ± 121.2 | 64.2 ± 92.8 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alvarez-Bermudez, M.D.; Martin-Reyes, F.; Ocaña-Wilhelmi, L.; Moreno-Ruiz, F.J.; Torres, J.A.; Fernandez-Garcia, D.; Valdes, S.; Moreno-Morales, N.; Garcia-Fuentes, E.; Tinahones, F.J.; et al. Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery. J. Clin. Med. 2020, 9, 3537. https://doi.org/10.3390/jcm9113537
Alvarez-Bermudez MD, Martin-Reyes F, Ocaña-Wilhelmi L, Moreno-Ruiz FJ, Torres JA, Fernandez-Garcia D, Valdes S, Moreno-Morales N, Garcia-Fuentes E, Tinahones FJ, et al. Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery. Journal of Clinical Medicine. 2020; 9(11):3537. https://doi.org/10.3390/jcm9113537
Chicago/Turabian StyleAlvarez-Bermudez, Maria D., Flores Martin-Reyes, Luis Ocaña-Wilhelmi, Francisco J. Moreno-Ruiz, Juan Alcaide Torres, Diego Fernandez-Garcia, Sergio Valdes, Noelia Moreno-Morales, Eduardo Garcia-Fuentes, Francisco J. Tinahones, and et al. 2020. "Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery" Journal of Clinical Medicine 9, no. 11: 3537. https://doi.org/10.3390/jcm9113537
APA StyleAlvarez-Bermudez, M. D., Martin-Reyes, F., Ocaña-Wilhelmi, L., Moreno-Ruiz, F. J., Torres, J. A., Fernandez-Garcia, D., Valdes, S., Moreno-Morales, N., Garcia-Fuentes, E., Tinahones, F. J., & Garrido-Sanchez, L. (2020). Variables Associated with Short-Term Weight Loss in a Cohort of Patients with Morbid Obesity According to Age and Three Types of Bariatric Surgery. Journal of Clinical Medicine, 9(11), 3537. https://doi.org/10.3390/jcm9113537